Over the last few years, we have seen the approval of the first disease-modifying therapies for Alzheimer’s disease, signifying a poignant turning point for the field. The next generation of therapeutics and diagnostics promises to define the future of treatments – based on the biology of aging approach – with

Sep 27, 2024 · more like this. Sion­na inks $191M IPO for cys­tic fi­bro­sis pipeline as Aard­vark eyes $89M for its own list­ing February 7, 2025; Less than two years af­ter block­buster IPO, Ace­lyrin ...

reset password. We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours. email

Oct 31, 2024 · Ar­genx’s Vyv­gart has beat sales ex­pec­ta­tions for the eleventh quar­ter in a row, sup­port­ed by strong up­take of a sub­cu­ta­neous ver­sion of the drug in …

Max Gelman writes about the big-picture ideas and trends that drive the biopharma world, with particular interests in immunology and neuroscience. A graduate of Northwestern University, Max joined ...

In the biopharma world, the new year doesn’t start on January 1 — it starts when the industry descends on San Francisco for JPM. Dealmakers, investors, and corporate leaders will gather to chart the course for 2025 and take stock of the landscape, both financial and political.

Jan 2, 2025 · 2024 was the year of the pri­vate megaround. Nine-fig­ure fi­nanc­ings dom­i­nat­ed biotech’s ven­ture fund­ing land­scape, with 96 such rounds tal­lied by End­points News.The bevy …

Biotech and pharma business news, with a focus on the science, people and money that drive the industry.

Zachary Brennan is senior editor for Endpoints, covering the US regulatory agency and others around the globe. He previously wrote about the FDA, Covid-19, and the biopharma industry for POLITICO ...

As a senior reporter, Kyle LaHucik covers the financial underpinnings of drug development and breaks news on biotech financing rounds, M&A, IPO planning and other deals pushing the industry forward.